EP4704980A2 - Manipulierte cytokine und verwendungen davon - Google Patents

Manipulierte cytokine und verwendungen davon

Info

Publication number
EP4704980A2
EP4704980A2 EP24726737.0A EP24726737A EP4704980A2 EP 4704980 A2 EP4704980 A2 EP 4704980A2 EP 24726737 A EP24726737 A EP 24726737A EP 4704980 A2 EP4704980 A2 EP 4704980A2
Authority
EP
European Patent Office
Prior art keywords
amino acid
composition
cytokine
seq
engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24726737.0A
Other languages
English (en)
French (fr)
Inventor
Louie HENDERSON
Oliver DUTTON
Falk Hoffmann
Sandro BOTTARO
Istvan REDL
Angela Rita ELIA
Carlo FISICARO
Benjamin Owens
Patrick Kunz
Matthew LAKINS
Patrik FOERCH
David Lowe
Kamil TAMIOLA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peptone Ltd
Original Assignee
Peptone Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptone Ltd filed Critical Peptone Ltd
Publication of EP4704980A2 publication Critical patent/EP4704980A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP24726737.0A 2023-05-04 2024-05-03 Manipulierte cytokine und verwendungen davon Pending EP4704980A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363500104P 2023-05-04 2023-05-04
PCT/IB2024/054340 WO2024228173A2 (en) 2023-05-04 2024-05-03 Engineered cytokines and uses thereof

Publications (1)

Publication Number Publication Date
EP4704980A2 true EP4704980A2 (de) 2026-03-11

Family

ID=91129512

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24726737.0A Pending EP4704980A2 (de) 2023-05-04 2024-05-03 Manipulierte cytokine und verwendungen davon

Country Status (3)

Country Link
US (1) US20260092094A1 (de)
EP (1) EP4704980A2 (de)
WO (1) WO2024228173A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025229623A1 (en) * 2024-05-03 2025-11-06 Peptone, Ltd. Engineered cytokines and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4029877B1 (de) * 2017-08-03 2024-01-17 Amgen Inc. Interleukin-21-muteine und verfahren zur behandlung
CN111205361B (zh) * 2018-11-22 2022-05-06 海珂分子（北京）科技有限责任公司 白介素21蛋白(il21)突变体及其应用
TWI826880B (zh) * 2020-12-23 2023-12-21 大陸商信達生物製藥（蘇州）有限公司 白細胞介素２１突變體以及其用途
WO2023046093A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种双特异性多肽复合物

Also Published As

Publication number Publication date
US20260092094A1 (en) 2026-04-02
WO2024228173A3 (en) 2024-12-12
WO2024228173A2 (en) 2024-11-07

Similar Documents

Publication Publication Date Title
Sawant et al. Toward drug-like multispecific antibodies by design
EP3167395B1 (de) Berechnungsverfahren für das design von proteinen
Stark et al. Boltzgen: Toward universal binder design
Klesmith et al. Fine epitope mapping of the CD19 extracellular domain promotes design
JP2004523754A (ja) Ｔ細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法
KR20040039328A (ko) 변형된 펙터 ⅸ
Guo et al. Protection against Th17 cells differentiation by an interleukin-23 receptor cytokine-binding homology region
JP2004529633A (ja) 低減された免疫原性を有する修飾されたヒトインターフェロンベータ
KR20030074789A (ko) 감소된 면역원성을 갖는 개질된 인간 뇌유래 신경영양인자 (ｂｄｎｆ）
US20260092094A1 (en) Engineered cytokines and uses thereof
Vasiliev et al. Structural and functional properties of IL-4δ2, an alternative splice variant of human IL-4
Shatov et al. The heterooligomerization of human small heat shock proteins is controlled by conserved motif located in the N-terminal domain
Carballo-Amador et al. Surface patches on recombinant erythropoietin predict protein solubility: engineering proteins to minimise aggregation
Rojas et al. Directed evolution of super-secreted variants from phage-displayed human Interleukin-2
JP2004519230A (ja) 低減された免疫原性を有する修飾されたインターロイキン−１受容体アンタゴニスト（ｉｌ−１ｒａ）
KR20030074788A (ko) 감소된 면역원성을 갖는 개질 렙틴
KR20030081479A (ko) 감소된 면역원성을 갖는 개질 인터페론 알파
KR20030082961A (ko) 감소된 면역원성을 갖는 개질 프로타민
JP2004535777A (ja) 低減された免疫原性を有する修飾された顆粒球マクロファージコロニー刺激因子（ｇｍ−ｃｓｆ）
WO2025229623A1 (en) Engineered cytokines and uses thereof
JP2005501546A (ja) 修飾されたヒト成長ホルモン
Baumann et al. Identification of a potential modification site in human stromal cell‐derived factor‐1
Cui et al. The role of the arginine residue in site RC for the analgesic activity of the recombinant Chinese scorpion Buthus martensii Karsch, BmK AGP-SYPU1
Nudelman et al. Intermolecular Interactions in a 44 kDa Interferon− Receptor Complex Detected by Asymmetric Reverse-Protonation and Two-Dimensional NOESY
JP2004526437A (ja) 低減された免疫原性を有する修飾されたケラチノサイト成長因子（ｋｇｆ）

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251029

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR